User:Mr. Ibrahem/Hydroxyethyl starch

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Hydroxyethyl starch
Clinical data
Trade namesHespan, Voluven, Volulyte, Tetrahes, Hestar, Others
Other namesTetrastarch, hetastarch
AHFS/Drugs.comHES 130/0.4: Monograph
Hetastarch: Monograph
Routes of
administration		Intravenous
Drug classVolume expander[1]
Pharmacokinetic data
Elimination half-life1.4 hrs
ExcretionKidney
Chemical and physical data
Molar mass130–200 kg/mol (typical)
3D model (JSmol)
  • O(CCO)[C@H]1O[C@@H]([C@@H](OCCO)[C@H](OCCO)[C@H]1OCCO)COCCO.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O
  • InChI=1S/C16H32O11.C6H12O6/c17-1-6-22-11-12-13(23-7-2-18)14(24-8-3-19)15(25-9-4-20)16(27-12)26-10-5-21;7-1-2-3(8)4(9)5(10)6(11)12-2/h12-21H,1-11H2;2-11H,1H2/t12-,13-,14+,15-,16+;2-,3-,4+,5-,6+/m11/s1 checkY
  • Key:DNZMDASEFMLYBU-RNBXVSKKSA-N checkY
  (verify)

Hydroxyethyl starch (HES), sold under the brand name Voluven among others, is a volume expander used to treat hypovolemia.[1] A crystalloid solution is generally preferred.[1] It is given by injection into a vein.[1]

Common side effects include itchiness.[1] Other side effects may include anaphylaxis, bleeding, heart failure, and shock.[1][2] Use in the critically ill is associated with an increased risk of death and kidney problems.[3] It is a manufactured colloid solution.[1]

Hydroxyethyl starch came into medical use in the 1960s.[4] Europe restricted their use in 2013, and removed them from market in 2018 due to associated side effects.[5][6] In the United States it costs about 80 USD for a 500 mL bag as of 2021.[7]

References[edit]

  1. ^ a b c d e f g h i "Hydroxyethyl Starch 130/0.4 Monograph for Professionals". Drugs.com. Archived from the original on 13 March 2016. Retrieved 10 December 2021.
  2. ^ a b "Hetastarch Monograph for Professionals". Drugs.com. Archived from the original on 21 May 2016. Retrieved 10 December 2021.
  3. ^ Zarychanski, R; Abou-Setta, AM; Turgeon, AF; Houston, BL; McIntyre, L; Marshall, JC; Fergusson, DA (Feb 20, 2013). "Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis". JAMA: The Journal of the American Medical Association. 309 (7): 678–88. doi:10.1001/jama.2013.430. PMID 23423413.
  4. ^ Bilotta, F; Giordano, G; Caroletti, F; Pugliese, F (June 2018). "Hydroxyethyl starch: the Paradigm of Eminence-Based Versus Evidence-Based Medicine-1". Turkish journal of anaesthesiology and reanimation. 46 (3): 165–167. doi:10.5152/TJAR.2018.030618. PMID 30140509.
  5. ^ "PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market". Archived from the original on 10 July 2021. Retrieved 10 December 2021.
  6. ^ "Hydroxyethyl-starch solutions for infusion to be suspended – CMDh endorses PRAC recommendation". Archived from the original on 14 November 2021. Retrieved 10 December 2021.
  7. ^ "Voluven Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 10 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Hydroxyethyl_starch&oldid=1212737531"